TY - JOUR
T1 - Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants
AU - Yeh, Sylvia H.
AU - Zangwill, Kenneth M.
AU - Lee, Hang
AU - Chang, Swei Ju
AU - Wong, Victor I.
AU - Greenberg, David P.
AU - Ward, Joel I.
N1 - Funding Information:
We gratefully acknowledge and thank members of the UCLA Center for Vaccine Research including Jennie Jing, Pat Wilson, Kim McMullin, Gloria Leon, Charlotte Gardea, Jeffree Sirowy, Candy Byers, Pam Hastings, Cathy Skokan, Melliie Badar, Liberty Teodoro, Carolyn Garcia and Ed Curry, MD, of Kaiser Permanente, Southern California Region, without whom this study would not have been completed. We would also like to thank Terry Thompson of the Centers for Disease Control and Prevention for his assistance with serotyping of selected isolates. This study was funded by NIH/NIAID Grant no. 1-AI-45249 and a grant from Merck Laboratories & Co.
PY - 2003/6/2
Y1 - 2003/6/2
N2 - Background: Streptococcus pneumoniae (Sp) is an important bacterial pathogen in children. Nasopharyngeal (NP) colonization of S. pneumoniae is necessary for person-to-person transmission and often precedes invasive disease. Methods: NP carriage of Sp was studied in 49 infants following administration of a heptavalent pneumococcal conjugate vaccine (PCV) conjugated to the outer membrane protein of serogroup b Neisseria meningitidis (vaccine serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F). The vaccine was administered at 2, 4, 6, and 12 months of age and carriage rates were compared to a concurrent group of 32 infants not given PCV and evaluated over the first 15 months of life. Results: Overall, Sp was isolated in 86/367 (23%) of NP cultures and 49% of infants. Serotype 23F was significantly less prevalent in the PCV group (1.9%) than the control group (16.1%) (P<0.05). Analysis of the proportion of children with prevalent carriage or acquisition of carriage did not differ between groups when evaluated by age or serotype. We noted, however, decreased acquisition and carriage in the vaccine group 1 month following the 12 month dose of PCV for vaccine serotypes (76 and 52% reduction, respectively), but this did not reach statistical significance (P=0.3). Adjustment for age, daycare and antibiotic use by multivariate modeling revealed no difference in carriage of vaccine containing serotypes or non-vaccine serotypes between groups. Conclusion: We did not show a significant effect of this heptavalent PCV on NP carriage. Further study of this issue, including a larger population size, is needed.
AB - Background: Streptococcus pneumoniae (Sp) is an important bacterial pathogen in children. Nasopharyngeal (NP) colonization of S. pneumoniae is necessary for person-to-person transmission and often precedes invasive disease. Methods: NP carriage of Sp was studied in 49 infants following administration of a heptavalent pneumococcal conjugate vaccine (PCV) conjugated to the outer membrane protein of serogroup b Neisseria meningitidis (vaccine serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F). The vaccine was administered at 2, 4, 6, and 12 months of age and carriage rates were compared to a concurrent group of 32 infants not given PCV and evaluated over the first 15 months of life. Results: Overall, Sp was isolated in 86/367 (23%) of NP cultures and 49% of infants. Serotype 23F was significantly less prevalent in the PCV group (1.9%) than the control group (16.1%) (P<0.05). Analysis of the proportion of children with prevalent carriage or acquisition of carriage did not differ between groups when evaluated by age or serotype. We noted, however, decreased acquisition and carriage in the vaccine group 1 month following the 12 month dose of PCV for vaccine serotypes (76 and 52% reduction, respectively), but this did not reach statistical significance (P=0.3). Adjustment for age, daycare and antibiotic use by multivariate modeling revealed no difference in carriage of vaccine containing serotypes or non-vaccine serotypes between groups. Conclusion: We did not show a significant effect of this heptavalent PCV on NP carriage. Further study of this issue, including a larger population size, is needed.
KW - Nasopharyngeal carriage
KW - Pneumococcal conjugate vaccine
UR - http://www.scopus.com/inward/record.url?scp=0038402699&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(03)00039-2
DO - 10.1016/S0264-410X(03)00039-2
M3 - Article
AN - SCOPUS:0038402699
SN - 0264-410X
VL - 21
SP - 2627
EP - 2631
JO - Vaccine
JF - Vaccine
IS - 19-20
ER -